Aripiprazole is metabolized mainly by CYP2D6 and CYP3A4. Strong inhibitors and inducers of these enzymes can significantly change aripiprazole levels. It also adds to the sedative and cardiovascular effects of many other drugs.
With: Strong CYP3A4 Inhibitors (eg, ketoconazole, clarithromycin, some HIV protease inhibitors)
Risk: Can increase aripiprazole levels, prolonging effects and raising the risk of side effects (akathisia, sedation, EPS).
Action: Dose reduction is often required. Prescribers should follow product-label guidance for dose changes and monitor closely for side effects.
With: Strong CYP3A4 Inducers (eg, carbamazepine, phenytoin, rifampin, St. John’s Wort)
Risk: Can lower aripiprazole levels by increasing metabolism, potentially causing loss of effect or relapse.
Action: Dose increases or alternative medications may be needed. Avoid combining with long-acting injectable forms when strong inducers are needed long term.
With: Strong CYP2D6 Inhibitors (eg, fluoxetine, paroxetine, quinidine)
Risk: Can significantly raise aripiprazole and active metabolite levels.
Action: Lower aripiprazole doses are usually recommended for most indications (not typically required for MDD adjunct use). Monitor for side effects.
With: Other Antipsychotics and Dopamine Antagonists (eg, risperidone, haloperidol, metoclopramide)
Risk: Additive risk of EPS, tardive dyskinesia, and QTc effects; may worsen Parkinson symptoms.
Action: Avoid unnecessary combinations. If switching antipsychotics, use careful cross-titration or taper strategies as recommended by guidelines.
With: Benzodiazepines, Opioids, and Other CNS Depressants
Risk: Increased sedation, dizziness, falls, and impaired judgment. Opioids also carry a boxed warning for combined CNS depression when used with other sedatives.
Action: Use lowest effective doses and avoid unnecessary polypharmacy. Warn patients about additive drowsiness and fall risk.
With: Anti-Parkinson Dopamine Agonists (eg, pramipexole, ropinirole)
Risk: Antagonistic effects—aripiprazole can worsen parkinsonian symptoms by blocking dopamine receptors.
Action: Use only when benefits outweigh risks. Prefer antipsychotics with lower dopamine blockade in Parkinson disease (eg, clozapine, quetiapine, or pimavanserin).
With: Drugs That Lower Seizure Threshold (eg, bupropion, tramadol, some antidepressants and antipsychotics)
Risk: Additive risk of seizures.
Action: Use caution in people with seizure risk factors; monitor closely and adjust medications as needed.
With: Antidiabetic Medications
Risk: Aripiprazole-induced hyperglycemia may make blood sugar harder to control.
Action: Monitor blood glucose more closely and adjust diabetes treatment according to standard diabetes care guidelines.